文献速递肿瘤 PET/CT骨显像与常规 SPECT

68Ga-PSMA-11 PET/CT在前列腺癌初始分期中:PSA与Gleason评分预测原发肿瘤示踪剂摄取强度

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-01-31

回顾性分析90例经活检证实的前列腺癌患者,采用68Ga-PSMA-11 PET/CT评估原发肿瘤及转移灶摄取强度。82例(91.1%)原发肿瘤呈病理性摄取,中位SUVmax 12.5 vs 正常前列腺3.9。Gleason评分>7或PSA≥10.0 ng/ml者摄取显著更高,作者建议此类患者优先应用该检查进行初始分期。

要点

  • 82例(91.1%)原发肿瘤SUVmax超过正常前列腺本底(中位12.5 vs 3.9)。
  • Gleason评分>7者原发肿瘤摄取显著高于评分6、7a、7b者(中位SUVmax 21.2 vs 5.9、8.3、8.2,p<0.001)。
  • PSA≥10.0 ng/ml者摄取显著高于PSA<10.0 ng/ml者(中位SUVmax 17.6 vs 7.7,p<0.001)。

核心结论

  • Gleason评分与PSA水平与原发肿瘤的68Ga-PSMA-11摄取强度相关。
  • Gleason评分6+7或PSA≤10 ng/ml的前列腺癌摄取显著较低,作者建议Gleason评分>7或PSA≥10 ng/ml的患者优先应用68Ga-PSMA-11 PET/CT进行初始分期。

研究设计与样本

  • 回顾性分析90例经直肠超声引导活检证实的前列腺癌患者(Gleason评分6-10,中位PSA 9.7 ng/ml),因初始分期转诊行68Ga-PSMA-11 PET/CT。
  • PET图像行视觉与半定量分析,测量原发肿瘤及可疑淋巴结或远处转移病灶的最大标准化摄取值(SUVmax),并与正常前列腺组织和臀肌的生理性本底活性比较。

主要发现

  • 82例(91.1%)原发肿瘤可见超过正常前列腺组织生理性摄取的病理性示踪剂积聚(中位SUVmax 12.5 vs 3.9)。
  • Gleason评分6、7a(3+4)、7b(4+3)者原发肿瘤中位SUVmax分别为5.9、8.3、8.2,显著低于Gleason评分>7者的21.2(p<0.001)。
  • PSA≥10.0 ng/ml者原发肿瘤中位SUVmax为17.6,显著高于PSA<10.0 ng/ml者的7.7(p<0.001)。
  • 24例(26.7%)检出82枚病理性示踪剂积聚的淋巴结,符合转移(中位SUVmax 10.6)。
  • 11例(12.2%)检出55处病理性骨病灶,可疑骨转移(中位SUVmax 11.6)。

关键数值与推荐

  • 原发肿瘤病理性摄取定义为超过正常前列腺组织生理性摄取,82例(91.1%)符合(中位SUVmax 12.5 vs 3.9)。
  • Gleason评分6、7a、7b者中位SUVmax分别为5.9、8.3、8.2,Gleason评分>7者为21.2(p<0.001)。
  • PSA≥10.0 ng/ml者中位SUVmax 17.6,PSA<10.0 ng/ml者7.7(p<0.001)。

临床怎么用

  • 作者建议,Gleason评分>7或PSA≥10 ng/ml的前列腺癌患者优先应用68Ga-PSMA-11 PET/CT进行初始分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate cancer (PC) cells typically show increased expression of prostate-specific membrane antigen (PSMA), which can be visualized by 68Ga-PSMA-11 PET/CT. The aim of this study was to assess the intensity of 68Ga-PSMA-11 uptake in the primary tumour and metastases in patients with biopsy-proven PC prior to therapy, and to determine whether a correlation exists between the primary tumour-related 68Ga-PSMA-11 accumulation and the Gleason score (GS) or prostate-specific antigen (PSA) level. METHODS: Ninety patients with transrectal ultrasound biopsy-proven PC (GS 6-10; median PSA: 9.7 ng/ml) referred for 68Ga-PSMA-11 PET/CT were retrospectively analysed. PET images were analysed visually and semiquantitatively by measuring the maximum standardized uptake value (SUVmax). The SUVmax of the primary tumour and pathologic lesions suspicious for lymphatic or distant metastases were then compared to the physiologic background activity of normal prostate tissue and gluteal muscle. The SUVmax of the primary tumour was assessed in relation to both PSA level and GS. RESULTS: Eighty-two patients (91.1%) demonstrated pathologic tracer accumulation in the primary tumour that exceeded physiologic tracer uptake in normal prostate tissue (median SUVmax: 12.5 vs. 3.9). Tumours with GS of 6, 7a (3+4) and 7b (4+3) showed significantly lower 68Ga-PSMA-11 uptake, with median SUVmax of 5.9, 8.3 and 8.2, respectively, compared to patients with GS >7 (median SUVmax: 21.2; p < 0.001). PC patients with PSA ≥10.0 ng/ml exhibited significantly higher uptake than those with PSA levels <10.0 ng/ml (median SUVmax: 17.6 versus 7.7; p < 0.001). In 24 patients (26.7%), 82 lymph nodes with pathologic tracer accumulation consistent with metastases were detected (median SUVmax: 10.6). Eleven patients (12.2%) revealed 55 pathologic osseous lesions suspicious for bone metastases (median SUVmax: 11.6). CONCLUSIONS: The GS and PSA level correlated with the intensity of tracer accumulation in the primary tumours of PC patients on 68Ga-PSMA-11 PET/CT. As PC tumours with GS 6+7 and patients with PSA values ≤10 ng/ml showed significantly lower 68Ga-PSMA-11 uptake, 68Ga-PSMA-11 PET/CT should be preferentially applied for primary staging of PC in patients with GS >7 or PSA levels ≥10 ng/ml.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017. PMID: 28138747. doi:10.1007/s00259-017-3631-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。